Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease

Detalhes bibliográficos
Autor(a) principal: Quadros, Kélcia R. S.
Data de Publicação: 2023
Outros Autores: Roza, Noemi A. V., França, Renata A., Esteves, André B. A., Barreto, Joaquim, Dominguez, Wagner V., Furukawa, Luzia N. S., Caramori, Jacqueline Teixeira [UNESP], Sposito, Andrei C., de Oliveira, Rodrigo Bueno
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1002/jbm4.10727
http://hdl.handle.net/11449/248368
Resumo: Advanced glycation end products (AGEs) accumulation may be involved in the progression of CKD-bone disorders. We sought to determine the relationship between AGEs measured in the blood, skin, and bone with histomorphometry parameters, bone protein, gene expression, and serum biomarkers of bone metabolism in patients with CKD stages 3 to 5D patients. Serum levels of AGEs were estimated by pentosidine, glycated hemoglobin (A1c), and N-carboxymethyl lysine (CML). The accumulation of AGEs in the skin was estimated from skin autofluorescence (SAF). Bone AGEs accumulation and multiligand receptor for AGEs (RAGEs) expression were evaluated by immunohistochemistry; bone samples were used to evaluate protein and gene expression and histomorphometric analysis. Data are from 86 patients (age: 51 ± 13 years; 60 [70%] on dialysis). Median serum levels of pentosidine, CML, A1c, and SAF were 71.6 pmol/mL, 15.2 ng/mL, 5.4%, and 3.05 arbitrary units, respectively. AGEs covered 3.92% of trabecular bone and 5.42% of the cortical bone surface, whereas RAGEs were expressed in 0.7% and 0.83% of trabecular and cortical bone surfaces, respectively. AGEs accumulation in bone was inversely related to serum receptor activator of NF-κB ligand/parathyroid hormone (PTH) ratio (R = −0.25; p = 0.03), and RAGE expression was negatively related to serum tartrate-resistant acid phosphatase-5b/PTH (R = −0.31; p = 0.01). Patients with higher AGEs accumulation presented decreased bone protein expression (sclerostin [1.96 (0.11–40.3) vs. 89.3 (2.88–401) ng/mg; p = 0.004]; Dickkopf-related protein 1 [0.064 (0.03–0.46) vs. 1.36 (0.39–5.87) ng/mg; p = 0.0001]; FGF-23 [1.07 (0.4–32.6) vs. 44.1 (6–162) ng/mg; p = 0.01]; and osteoprotegerin [0.16 (0.08–2.4) vs. 6.5 (1.1–23.7) ng/mg; p = 0.001]), upregulation of the p53 gene, and downregulation of Dickkopf-1 gene expression. Patients with high serum A1c levels presented greater cortical porosity and Mlt and reduced osteoblast surface/bone surface, eroded surface/bone surface, osteoclast surface/bone surface, mineral apposition rate, and adjusted area. Cortical thickness was negatively correlated with serum A1c (R = −0.28; p = 0.02) and pentosidine levels (R = −0.27; p = 0.02). AGEs accumulation in the bone of CKD patients was related to decreased bone protein expression, gene expression changes, and increased skeletal resistance to PTH; A1c and pentosidine levels were related to decreased cortical thickness; and A1c levels were related to increased cortical porosity and Mlt. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
id UNSP_fe22b29750ee26014565f159d950e37b
oai_identifier_str oai:repositorio.unesp.br:11449/248368
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney DiseaseADVANCED GLYCATION END PRODUCTSBONE METABOLISMCHRONIC KIDNEY DISEASEAdvanced glycation end products (AGEs) accumulation may be involved in the progression of CKD-bone disorders. We sought to determine the relationship between AGEs measured in the blood, skin, and bone with histomorphometry parameters, bone protein, gene expression, and serum biomarkers of bone metabolism in patients with CKD stages 3 to 5D patients. Serum levels of AGEs were estimated by pentosidine, glycated hemoglobin (A1c), and N-carboxymethyl lysine (CML). The accumulation of AGEs in the skin was estimated from skin autofluorescence (SAF). Bone AGEs accumulation and multiligand receptor for AGEs (RAGEs) expression were evaluated by immunohistochemistry; bone samples were used to evaluate protein and gene expression and histomorphometric analysis. Data are from 86 patients (age: 51 ± 13 years; 60 [70%] on dialysis). Median serum levels of pentosidine, CML, A1c, and SAF were 71.6 pmol/mL, 15.2 ng/mL, 5.4%, and 3.05 arbitrary units, respectively. AGEs covered 3.92% of trabecular bone and 5.42% of the cortical bone surface, whereas RAGEs were expressed in 0.7% and 0.83% of trabecular and cortical bone surfaces, respectively. AGEs accumulation in bone was inversely related to serum receptor activator of NF-κB ligand/parathyroid hormone (PTH) ratio (R = −0.25; p = 0.03), and RAGE expression was negatively related to serum tartrate-resistant acid phosphatase-5b/PTH (R = −0.31; p = 0.01). Patients with higher AGEs accumulation presented decreased bone protein expression (sclerostin [1.96 (0.11–40.3) vs. 89.3 (2.88–401) ng/mg; p = 0.004]; Dickkopf-related protein 1 [0.064 (0.03–0.46) vs. 1.36 (0.39–5.87) ng/mg; p = 0.0001]; FGF-23 [1.07 (0.4–32.6) vs. 44.1 (6–162) ng/mg; p = 0.01]; and osteoprotegerin [0.16 (0.08–2.4) vs. 6.5 (1.1–23.7) ng/mg; p = 0.001]), upregulation of the p53 gene, and downregulation of Dickkopf-1 gene expression. Patients with high serum A1c levels presented greater cortical porosity and Mlt and reduced osteoblast surface/bone surface, eroded surface/bone surface, osteoclast surface/bone surface, mineral apposition rate, and adjusted area. Cortical thickness was negatively correlated with serum A1c (R = −0.28; p = 0.02) and pentosidine levels (R = −0.27; p = 0.02). AGEs accumulation in the bone of CKD patients was related to decreased bone protein expression, gene expression changes, and increased skeletal resistance to PTH; A1c and pentosidine levels were related to decreased cortical thickness; and A1c levels were related to increased cortical porosity and Mlt. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.National Research CouncilFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Nephrology Division School of Medical Sciences University of Campinas (Unicamp)Laboratory for Evaluation of Mineral and Bone Disorders in Nephrology (LEMON) School of Medical Sciences University of Campinas (Unicamp)Laboratory of Renal Pathophysiology LIM-16 Department of Internal Medicine School of Medicine University of São PauloDepartment of Internal Medicine Botucatu School of Medicine UNESPLaboratory of Atherosclerosis and Vascular Biology Cardiology Division School of Medical Sciences University of Campinas (Unicamp)Department of Internal Medicine Botucatu School of Medicine UNESPFAPESP: 2015/16544-5Universidade Estadual de Campinas (UNICAMP)Universidade de São Paulo (USP)Universidade Estadual Paulista (UNESP)Quadros, Kélcia R. S.Roza, Noemi A. V.França, Renata A.Esteves, André B. A.Barreto, JoaquimDominguez, Wagner V.Furukawa, Luzia N. S.Caramori, Jacqueline Teixeira [UNESP]Sposito, Andrei C.de Oliveira, Rodrigo Bueno2023-07-29T13:42:03Z2023-07-29T13:42:03Z2023-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/jbm4.10727JBMR Plus, v. 7, n. 3, 2023.2473-4039http://hdl.handle.net/11449/24836810.1002/jbm4.107272-s2.0-85148247733Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJBMR Plusinfo:eu-repo/semantics/openAccess2024-08-14T17:23:32Zoai:repositorio.unesp.br:11449/248368Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:23:32Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
title Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
spellingShingle Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
Quadros, Kélcia R. S.
ADVANCED GLYCATION END PRODUCTS
BONE METABOLISM
CHRONIC KIDNEY DISEASE
title_short Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
title_full Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
title_fullStr Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
title_full_unstemmed Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
title_sort Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
author Quadros, Kélcia R. S.
author_facet Quadros, Kélcia R. S.
Roza, Noemi A. V.
França, Renata A.
Esteves, André B. A.
Barreto, Joaquim
Dominguez, Wagner V.
Furukawa, Luzia N. S.
Caramori, Jacqueline Teixeira [UNESP]
Sposito, Andrei C.
de Oliveira, Rodrigo Bueno
author_role author
author2 Roza, Noemi A. V.
França, Renata A.
Esteves, André B. A.
Barreto, Joaquim
Dominguez, Wagner V.
Furukawa, Luzia N. S.
Caramori, Jacqueline Teixeira [UNESP]
Sposito, Andrei C.
de Oliveira, Rodrigo Bueno
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual de Campinas (UNICAMP)
Universidade de São Paulo (USP)
Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Quadros, Kélcia R. S.
Roza, Noemi A. V.
França, Renata A.
Esteves, André B. A.
Barreto, Joaquim
Dominguez, Wagner V.
Furukawa, Luzia N. S.
Caramori, Jacqueline Teixeira [UNESP]
Sposito, Andrei C.
de Oliveira, Rodrigo Bueno
dc.subject.por.fl_str_mv ADVANCED GLYCATION END PRODUCTS
BONE METABOLISM
CHRONIC KIDNEY DISEASE
topic ADVANCED GLYCATION END PRODUCTS
BONE METABOLISM
CHRONIC KIDNEY DISEASE
description Advanced glycation end products (AGEs) accumulation may be involved in the progression of CKD-bone disorders. We sought to determine the relationship between AGEs measured in the blood, skin, and bone with histomorphometry parameters, bone protein, gene expression, and serum biomarkers of bone metabolism in patients with CKD stages 3 to 5D patients. Serum levels of AGEs were estimated by pentosidine, glycated hemoglobin (A1c), and N-carboxymethyl lysine (CML). The accumulation of AGEs in the skin was estimated from skin autofluorescence (SAF). Bone AGEs accumulation and multiligand receptor for AGEs (RAGEs) expression were evaluated by immunohistochemistry; bone samples were used to evaluate protein and gene expression and histomorphometric analysis. Data are from 86 patients (age: 51 ± 13 years; 60 [70%] on dialysis). Median serum levels of pentosidine, CML, A1c, and SAF were 71.6 pmol/mL, 15.2 ng/mL, 5.4%, and 3.05 arbitrary units, respectively. AGEs covered 3.92% of trabecular bone and 5.42% of the cortical bone surface, whereas RAGEs were expressed in 0.7% and 0.83% of trabecular and cortical bone surfaces, respectively. AGEs accumulation in bone was inversely related to serum receptor activator of NF-κB ligand/parathyroid hormone (PTH) ratio (R = −0.25; p = 0.03), and RAGE expression was negatively related to serum tartrate-resistant acid phosphatase-5b/PTH (R = −0.31; p = 0.01). Patients with higher AGEs accumulation presented decreased bone protein expression (sclerostin [1.96 (0.11–40.3) vs. 89.3 (2.88–401) ng/mg; p = 0.004]; Dickkopf-related protein 1 [0.064 (0.03–0.46) vs. 1.36 (0.39–5.87) ng/mg; p = 0.0001]; FGF-23 [1.07 (0.4–32.6) vs. 44.1 (6–162) ng/mg; p = 0.01]; and osteoprotegerin [0.16 (0.08–2.4) vs. 6.5 (1.1–23.7) ng/mg; p = 0.001]), upregulation of the p53 gene, and downregulation of Dickkopf-1 gene expression. Patients with high serum A1c levels presented greater cortical porosity and Mlt and reduced osteoblast surface/bone surface, eroded surface/bone surface, osteoclast surface/bone surface, mineral apposition rate, and adjusted area. Cortical thickness was negatively correlated with serum A1c (R = −0.28; p = 0.02) and pentosidine levels (R = −0.27; p = 0.02). AGEs accumulation in the bone of CKD patients was related to decreased bone protein expression, gene expression changes, and increased skeletal resistance to PTH; A1c and pentosidine levels were related to decreased cortical thickness; and A1c levels were related to increased cortical porosity and Mlt. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
publishDate 2023
dc.date.none.fl_str_mv 2023-07-29T13:42:03Z
2023-07-29T13:42:03Z
2023-03-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1002/jbm4.10727
JBMR Plus, v. 7, n. 3, 2023.
2473-4039
http://hdl.handle.net/11449/248368
10.1002/jbm4.10727
2-s2.0-85148247733
url http://dx.doi.org/10.1002/jbm4.10727
http://hdl.handle.net/11449/248368
identifier_str_mv JBMR Plus, v. 7, n. 3, 2023.
2473-4039
10.1002/jbm4.10727
2-s2.0-85148247733
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv JBMR Plus
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128164842438656